Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis
出版年份 2014 全文链接
标题
Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis
作者
关键词
-
出版物
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 59, Issue 1, Pages 38-45
出版商
American Society for Microbiology
发表日期
2014-10-14
DOI
10.1128/aac.03931-14
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The pyrazinamide susceptibility breakpoint above which combination therapy fails
- (2014) T. Gumbo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
- (2013) J. G. Pasipanodya et al. JOURNAL OF INFECTIOUS DISEASES
- The Evaluation of Multivariate Adaptive Regression Splines for the Prediction of Antitumor Activity of Acridinone Derivatives
- (2013) Marcin Koba et al. Medicinal Chemistry
- A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture
- (2012) E. Chigutsa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- TheSLCO1B1rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
- (2011) Emmanuel Chigutsa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients
- (2011) Siv Jönsson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling
- (2011) Shashikant Srivastava et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients
- (2011) Justin J. Wilkins et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial
- (2010) Marianne E Visser et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability
- (2010) T. Gumbo ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania
- (2010) Mbazi Senkoro et al. BMC INFECTIOUS DISEASES
- Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity
- (2010) Geraint R. Davies TUBERCULOSIS
- Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis
- (2009) D. Almeida et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
- (2009) T. Gumbo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana
- (2009) Sekai Chideya et al. CLINICAL INFECTIOUS DISEASES
- Quantitative Drug Susceptibility Testing of Mycobacterium tuberculosis by Use of MGIT 960 and EpiCenter Instrumentation
- (2009) B. Springer et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Comparison of multivariate adaptive regression splines and logistic regression in detecting SNP–SNP interactions and their application in prostate cancer
- (2008) Hui-Yi Lin et al. JOURNAL OF HUMAN GENETICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started